A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)

Respiratory Research

Volumn 17, Issue 1, 2016, Pages

  Iwata, Takekazu ^a   Yoshino, Ichiro ^a   Yoshida, Shigetoshi ^a   Ikeda, Norihiko ^b   Tsuboi, Masahiro ^c   Asato, Yuji ^d   Katakami, Nobuyuki ^e   Sakamoto, Kazuhiro ^f   Yamashita, Yoshinori ^g   Okami, Jiro ^h   Mitsudomi, Tetsuya ⁱ   Yamashita, Motohiro ^j   Yokouchi, Hiroshi ^k   Okubo, Kenichi ^l   Okada, Morihito ^m   Takenoyama, Mitsuhiro ⁿ   Chida, Masayuki ^o   Tomii, Keisuke ^p   Matsuura, Motoki ^q   Azuma, Arata ^r   Iwasawa, Tae ^s   Kuwano, Kazuyoshi ^t   Sakai, Shuji ^u   Hiroshima, Kenzo ^u   Fukuoka, Junya ^v   Yoshimura, Kenichi ^w   Tada, Hirohito ^x   Nakagawa, Kazuhiko ⁱ   Nakanishi, Yoichi ^y   more..

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION YOKOHAMA MEDICAL CENTER   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^k FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^l TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^m HIROSHIMA UNIVERSITY   (Japan)

ⁿ NATIONAL KYUSHU CANCER CENTER   (Japan)

^o DOKKYO MEDICAL UNIVERSITY   (Japan)

^p KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^q HIROSHIMA CITY HOSPITAL   (Japan)

^r NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

^s Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^t JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^u TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^v NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^w KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^x Suita City Hospital   (Japan)

^y KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Acute exacerbation; Idiopathic pulmonary fibrosis; Lung cancer; Pirfenidone; Surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; PIRFENIDONE; PYRIDONE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ATRIAL FIBRILLATION; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER STAGING; CELLULAR NONSPECIFIC INTERSTITIAL PNEUMONIA; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOALUBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOCYTE COUNT; LOBECTOMY; LUNG CANCER; LUNG RESECTION; LUNG SURGERY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; ONCOLOGY; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; RESPIRATORY BRONCHIOLITIS; RESPIRATORY FAILURE; SIDE EFFECT; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; WOUND DEHISCENCE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; LUNG TUMOR; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; LUNG NEOPLASMS; PNEUMONECTOMY; PYRIDONES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84979009556     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-016-0398-4     Document Type: Article

References (32)

1. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5-8.
2. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132:1652-8.
3. Hoshikawa Y, Kondo T. Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection. Nihon Geka Gakkai Zasshi. 2004;105:757-62.
4. Kumar P, Goldstraw P, Yamada K, Nicholson AG, Wells AU, Hansell DM, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125:1321-7.
5. Yoshimura K, Miyamoto A, Uruga H, Morokawa N, Beika Y, Kishi K. A nation-wide survey on prophylaxis for acute exacerbation of idiopathic pulmonary fibrosis following lung surgery for associated lung cancer. The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2008. 2009;77-81.
6. Masuda M, Kuwano H, Okumura M, Arai H, Endo S, Doki Y, et al. Thoracic and cardiovascular surgery in Japan during 2013. Gen Thorac Cardiovasc Surg. 2015;63:670-701.
7. Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41:e161-5.
8. Yamauchi Y, Izumi Y, Inoue M, Sugiura H, Goto T, Anraku M, et al. Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS One. 2011;6:e29053.
9. Ito H, Nakayama H, Yokose T, Yamada K. Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection. Asian Cardiovasc Thorac Ann. 2014;8:948-54.
10. Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604-11.
11. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367-73.
12. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.
13. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
14. Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2008;136:1357-63.
15. Shintani Y, Ohta M, Iwasaki T, Ikeda N, Tomita E, Kawahara K, et al. Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer. Gen Thorac Cardiovasc Surg. 2010;58:182-5.
16. Japanese Respiratory Society. Idiopathic interstitial pneumonias: diagnosis and treatment. 2nd ed. Tokyo: Nankodo; 2011. p. 67-73.
17. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King Jr TE, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636-43.
18. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-9.
19. Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812-7.
20. Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg. 2013;61:254-61.
21. Masuda M, Kuwano H, Okumura M, Amano J, Arai H, Endo S, et al. Thoracic and cardiovascular surgery in Japan during 2012: annual report by the Japanese Association for thoracic surgery. Gen Thorac Cardiovasc Surg. 2014;62:734-64.
22. Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149:64-9.
23. Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85:326-31.
24. Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011;71:70-4.
25. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6:1242-6.
26. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-9.
27. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-7.
28. Iwata T, Yoshida S, Nagato K, Nakajima T, Suzuki H, Tagawa T, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015;45:1263-70.
29. Sugiura H, Takeda A, Hoshi T, Kawabata Y, Sayama K, Jinzaki M, et al. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg. 2012;93:937-43.
30. Yano M, Sasaki H, Moriyama S, Hikosaka Y, Yokota K, Kobayashi S, et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg. 2012;14:146-50.
31. Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K, et al. Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg. 2015;100:954-60.
32. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.